Cargando…

Cusatuzumab plus azacitidine in Japanese patients with newly diagnosed acute myeloid leukemia ineligible for intensive treatment

We present the results of a phase 1 study that evaluated the safety, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary disease response to cusatuzumab, a novel anti‐CD70 monoclonal antibody, in combination with azacitidine, in newly diagnosed acute myeloid leukemia Japanese partici...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ikezoe, Takayuki, Usuki, Kensuke, Aida, Kensuke, Hatayama, Tomoyoshi, Shirahase, Toru, Yamauchi, Takahiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	ORIGINAL ARTICLES
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9986061/ https://www.ncbi.nlm.nih.gov/pubmed/36394119 http://dx.doi.org/10.1111/cas.15663

Ejemplares similares

Venetoclax plus azacitidine in Japanese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy
por: Yamamoto, Kazuhito, et al.
Publicado: (2021)

Results from a phase I/II trial of cusatuzumab combined with azacitidine in patients with newly diagnosed acute myeloid leukemia who are ineligible for intensive chemotherapy
por: Pabst, Thomas, et al.
Publicado: (2023)

Correction to: Venetoclax plus azacitidine in Japanese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy
Publicado: (2023)

Venetoclax plus low-dose cytarabine in Japanese patients with untreated acute myeloid leukaemia ineligible for intensive chemotherapy
por: Yamauchi, Takahiro, et al.
Publicado: (2021)

Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3(mut+) AML ineligible for intensive chemotherapy
por: Wang, Eunice S., et al.
Publicado: (2022)

Venetoclax plus low-dose cytarabine in patients with newly diagnosed acute myeloid leukemia ineligible for intensive chemotherapy: an expanded access study in Japan
por: Asada, Noboru, et al.
Publicado: (2023)

Venetoclax and Azacitidine in Chinese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy
por: Xia, Leiming, et al.
Publicado: (2023)

Evaluation of azacitidine in patients with transplant-ineligible myelodysplastic syndromes and acute myeloid leukemia with myelodysplasia-related changes in a Japanese clinical setting
por: Nakaya, Aya, et al.
Publicado: (2020)

Retrospective, real‐life study of venetoclax plus azacitidine or low‐dose cytarabine in French patients with acute myeloid leukemia ineligible for intensive chemotherapy
por: Laloi, Louise, et al.
Publicado: (2022)

Azacitidine Plus Venetoclax for the Treatment of Relapsed and Newly Diagnosed Acute Myeloid Leukemia Patients
por: Garciaz, Sylvain, et al.
Publicado: (2022)

Predictors of the Overall Survival with Azacitidine Monotherapy in Untreated Acute Myeloid Leukemia Patients Ineligible for Intensive Therapy
por: Taenaka, Ryutaro, et al.
Publicado: (2022)

Subcutaneous azacitidine maintenance in transplant-ineligible patients with acute myeloid leukemia: a single-center retrospective study
por: Johnson, Natacha, et al.
Publicado: (2023)

Cost-Effectiveness Analysis of Venetoclax in Combination with Azacitidine Versus Azacitidine Monotherapy in Patients with Acute Myeloid Leukemia Who are Ineligible for Intensive Chemotherapy: From a US Third Party Payer Perspective
por: Pratz, Keith W., et al.
Publicado: (2022)

An open‐label, nonrandomized, phase Ib feasibility study of cusatuzumab in patients with nasopharyngeal carcinoma
por: De Meulenaere, Astrid, et al.
Publicado: (2021)

Radical surgery and venetoclax plus azacitidine in an octogenarian with acute myeloid leukemia
por: Ramdohr, Florian, et al.
Publicado: (2022)

Venetoclax for the treatment of newly diagnosed acute myeloid leukemia in patients who are ineligible for intensive chemotherapy
por: Richard-Carpentier, Guillaume, et al.
Publicado: (2019)

Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia
por: Cherry, Evan M., et al.
Publicado: (2021)

Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA
por: Facon, Thierry, et al.
Publicado: (2022)

PB1849: TRIAL IN PROGRESS: PHASE IB/II STUDY OF SIREMADLIN IN COMBINATION WITH VENETOCLAX + AZACITIDINE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY
por: Daver, N. G., et al.
Publicado: (2022)

High CRP-albumin ratio predicts poor prognosis in transplant ineligible elderly patients with newly diagnosed acute myeloid leukemia
por: Senjo, Hajime, et al.
Publicado: (2022)

Randomized study of continuous high-dose lenalidomide, sequential azacitidine and lenalidomide, or azacitidine in persons 65 years and over with newly-diagnosed acute myeloid leukemia
por: Medeiros, Bruno C., et al.
Publicado: (2018)

Azacytidine plus olaparib for relapsed acute myeloid leukaemia, ineligible for intensive chemotherapy, diagnosed with a synchronous malignancy
por: Iluta, Sabina, et al.
Publicado: (2021)

Clinical profile of gilteritinib in Japanese patients with relapsed/refractory acute myeloid leukemia: An open‐label phase 1 study
por: Usuki, Kensuke, et al.
Publicado: (2018)

Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia
por: DiNardo, Courtney D., et al.
Publicado: (2021)

The AGILE trial of ivosidenib plus azacitidine versus azacitidine alone: How many limitations is too many?
por: Bhatt, Anjali, et al.
Publicado: (2022)

Azacitidine vs. Decitabine in Unfit Newly Diagnosed Acute Myeloid Leukemia Patients: Results from the PETHEMA Registry
por: Labrador, Jorge, et al.
Publicado: (2022)

Venetoclax in Combination with Azacitidine for the Treatment of Newly Diagnosed Acute Myeloid Leukemia: A Canadian Cost–Utility Analysis
por: Guinan, Kimberly, et al.
Publicado: (2022)

Higher-dose venetoclax with measurable residual disease-guided azacitidine discontinuation in newly diagnosed acute myeloid leukemia
por: Gutman, Jonathan A., et al.
Publicado: (2023)

Outcome of therapy-related myeloid neoplasms treated with azacitidine
por: Fianchi, Luana, et al.
Publicado: (2012)

Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma
por: Facon, Thierry, et al.
Publicado: (2021)

Impact of Treatment Sequencing on Overall Survival in Patients with Transplant-Ineligible Newly Diagnosed Myeloma
por: Fonseca, Rafael, et al.
Publicado: (2023)

PB1857: VENETOCLAX, AZACITIDINE, COMBINED WITH LOW-DOSE CYTARABINE IN OLDERLY OR UNFIT PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA
por: Han, Xiao, et al.
Publicado: (2023)

P14: DREAMM-9: PHASE I STUDY OF BELANTAMAB MAFODOTIN PLUS STANDARD OF CARE IN PATIENTS WITH TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA
por: Usmani, S, et al.
Publicado: (2022)

P942: DREAMM-9: PHASE I STUDY OF BELANTAMAB MAFODOTIN PLUS STANDARD OF CARE IN PATIENTS WITH TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA
por: Usmani, S. Z., et al.
Publicado: (2022)

Efficacy and safety of isatuximab plus bortezomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma ineligible/with no immediate intent for autologous stem cell transplantation
por: Ocio, Enrique M., et al.
Publicado: (2023)

Randomized phase-II trial evaluating induction therapy with idarubicin and etoposide plus sequential or concurrent azacitidine and maintenance therapy with azacitidine
por: Schlenk, R. F., et al.
Publicado: (2019)

Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML
por: Sekeres, Mikkael A., et al.
Publicado: (2021)

Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML
por: Adès, Lionel, et al.
Publicado: (2022)

Venetoclax with Decitabine or Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia
por: Bouligny, Ian M., et al.
Publicado: (2023)

The Ineligibility of Antipyrin in Pneumonia
Publicado: (1886)

Cannot write session to /tmp/vufind_sessions/sess_k03kd64508mg6m2r4mn54gnfc6